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Interpretation — In routine clinical practice, we observed 
no overall clinically relevant difference in the risks of VTE 
and major bleeding within 90 days of THA with respect to 
thromboprophylaxis duration. However, our data indicate 
that short-term thromboprophylaxis started postoperatively 
is associated with increased 90-day mortality. The signifi-
cance of these data should be explored further.
The incidence of total hip arthroplasty (THA) procedures 
increases annually worldwide (Nemes et al. 2014). Risk of 
symptomatic venous thromboembolism (VTE) within 90 days 
of THA are reported to range from 1% to 4% (Pedersen et al. 
2012, Huo 2012, Wolf et al. 2012) in the presence of thrombo-
prophylaxis, and is furthermore elevated up to 1 year postop-
eratively (Pedersen et al. 2012). Given the high risk of VTE in 
the absence of thromboprophylaxis and high mortality follow-
ing symptomatic VTE (Pedersen et al. 2017), anticoagulant 
thromboprophylaxis for THA patients is preferred treatment 
in most countries. However, the recommended optimal dura-
tion of the treatment has been a matter of debate for years. 
The American College of Chest Physicians (ACCP) guide-
lines from 2012 recommend a minimum of 10 to 14 days of 
thromboprophylaxis and suggest extending the treatment to 35 
days in the outpatient period (Falck-Ytter et al. 2012). The 
American Academy of Orthopaedic Surgeons (AAOS) guide-
lines from 2011 recommend individual assessment of the opti-
mal duration of thromboprophylaxis (AAOS 2013). Since a 
number of concerns have been identified with these guidelines 
(Budhiparama et al. 2014), and due to considerable change in 
the THA course with introduction of fast-track programs in 
Background and purpose — The recommended opti-
mal duration of the thromboprophylaxis treatment in total 
hip arthroplasty (THA) patients has been a matter of debate 
for years. We examined the association between short (1–5 
days), standard (6–14 days), and extended (≥ 15 days) dura-
tion of thromboprophylaxis, with regards to the risk of 
venous thromboembolism (VTE), major bleeding, and death 
in unselected THA patients.
Patients and methods — We performed a cohort study 
using prospectively collected data from the population-
based hip arthroplasty registries, prescription databases, and 
patient administrative registries in Denmark and Norway. We 
included 55,540 primary THA patients with osteoarthritis
Results — The 90-day cumulative incidence of VTE 
was 1.0% for patients with standard treatment (reference), 
1.1% for those with short-term treatment (adjusted hazard 
ratio [aHR] of 1.1, 95% confidence interval (CI) 0.8–1.5) 
and 1.0% for those with extended treatment (aHR of 0.9, CI 
0.8–1.2). The aHRs for major bleeding were 1.1 (CI 0.8–1.6) 
for short and 0.8 (CI 0.6–1.1) for extended vs. standard treat-
ment. In addition, patients with short and extended treatment 
had aHRs for death of 1.2 (CI 0.8–1.8) and 0.8 (CI 0.5–1.1) 
vs. standard treatment, respectively. Patients who started 
short treatment postoperatively had an aHR for death of 1.8 
(CI 1.1–3.1) and absolute risk difference of 0.2%, whereas 
patients who started short treatment preoperatively had an 
aHR for death of 0.5 (CI 0.2–1.2) and absolute risk differ-
ence of 0.3% compared with patients who had standard treat-
ment with post- and preoperative start, respectively.
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orthopedic departments, several national guidelines have been 
published since. Danish national guidelines recommend anti-
coagulant thromboprophylaxis for 6–10 days in THA patients, 
and less than 5 days if fast-track THA surgery was performed 
(Danish Council for the Use of Expensive Hospital Medicine 
[RADS] 2016). In Norway, thromboprophylaxis is recom-
mended for 10 postoperative days (Granan 2015). The latest 
paper from the Cochrane database of systematic reviews con-
cluded that there is moderate quality evidence for extended 
duration of thromboprophylaxis to prevent VTE in THA 
patients (Forster and Stewart 2016). Neither of the guidelines 
suggests risk stratification in order to provide specific duration 
of thromboprophylaxis for specific THA patients. A Danish 
cohort study observed no overall difference in the risk of VTE 
or bleeding with respect to thromboprophylaxis duration in 
THA patients from routine clinical practice (Pedersen et al. 
2015), but this study lacked statistical power to analyze data 
on the subgroup level. 
We examined the association between duration of antico-
agulant thromboprophylaxis for the prevention of VTE in 
patients undergoing elective THA in Denmark and Norway. 
As a safety outcome, we consider bleeding and death. We 
also aimed to identify THA patients who could benefit from 
extended prophylaxis without increase in bleeding events. 
Patients and methods
Study design and setting
We conducted this population-based cohort study using pro-
spectively collected data available from the Nordic Arthro-
plasty Register Association (NARA) database, established in 
2009. All Swedish, Norwegian, Danish, and Finnish citizens 
are assigned a unique civil registration number, permitting 
unambiguous linkage between hip registries and other medi-
cal databases in each country. This also enables tracking of 
deceased and emigrated patients (Schmidt et al. 2014). The 
healthcare system in Scandinavian countries provides tax-
supported healthcare for all citizens; free medical care is guar-
anteed for emergency and general hospital admissions, as well 
as for outpatient clinic visits. The study is reported according 
to the RECORD guidelines.
Study population
We used the NARA database to identify all patients operated 
in Denmark and Norway. Data from Sweden and Finland were 
not included, since individual-level data on duration of anti-
coagulant thromboprophylaxis were not available from these 
countries. We included all primary THAs between January 
1, 2010 and December 31, 2014 from Denmark (n = 34,625) 
and between January 1, 2008 and December 31, 2013 from 
Norway (n = 34,801), and accessed their preoperative and sur-
gery-related records. Primary THA was defined as insertion of 
a unilateral total hip prosthesis due to primary osteoarthritis. 
We excluded 269 and 261 patients from Denmark and 
Norway, respectively, since these were registered in NARA as 
not receiving any anticoagulant thromboprophylaxis, leaving 
34,356 Norwegian and 34,540 Danish THAs in the study pop-
ulation. We restricted the study population to first-time THA 
due to primary OA, leaving 26,250 THA patients in Denmark 
and 31,096 patients in Norway. We excluded 1,806 patients 
from Norway due to registration of several thromboprophy-
laxis drugs as the first choice. Finally, 2,310 procedures in 
Denmark and 2,748 in Norway lacked information on dura-
tion of thromboprophylaxis, although they were registered as 
receiving thromboprophylaxis, which resulted in 23,940 and 
26,542 procedures for the complete-case analyses.
Duration of anticoagulant thromboprophylaxis
We categorized the duration of anticoagulant thrombopro-
phylaxis prescribed by surgeon in relation to THA surgery 
as short-term (1–5 days), standard (6–14 days), or extended 
(≥ 15 days) based on available international guidelines 
for thromboprophylaxis and clinical practice in Denmark 
and Norway. Allocation of duration of treatment is depen-
dent on the local guidelines at the individual departments. 
Hence, most standard patients operated at one department 
will receive the same length of treatment irrespective of their 
risk. However, high-risk patients such as those with previ-
ous VTE or cancer have a higher likelihood of receiveing 
extended prophylaxis. We included the following anticoagu-
lant agents approved for use in the Denmark and Norway for 
prevention of VTE in THA patients: parenteral low-molec-
ular-weight heparin (including enoxaparin, dalteparin, and 
tinzaparin) and fondaparinux, dabigatran, and rivaroxaban, 
initiated both pre- and postoperatively. Mechanical throm-
boprophylaxis, when used, is combined with anticoagulant 
thromboprophylaxis. 
Outcome
The outcomes of interest were VTE, major bleeding, and 
death. These data were obtained from the Danish National 
Patient Registry (DNRP) (Schmidt et al. 2015) and the Nor-
wegian Patient Register (NPR) (Bakken et al. 2004). The 
effectiveness outcome in our analyses was VTE, including 
deep venous thrombosis (DVT) and pulmonary embolism 
(PE), whereas safety outcome was death and major bleeding 
events, including intracranial bleeding, gastrointestinal bleed-
ing, and urinary/lung bleeding. The proportion of hospitalized 
patients correctly registered in the DNRP and NPR with car-
diovascular events and major bleeding has been reported as 
75% to 95% (Adelborg et al. 2016, Sundboll et al. 2016). Both 
primary and secondary diagnoses, which were coded by the 
physician at the discharge from the hospital or during the out-
patient visit, were included in our study. 
Outcome data from general practitioners were not available. 
Since any suspicion of VTE and major bleeding would lead 
to hospitalization or outpatient clinic visit of the majority of 
300 Acta Orthopaedica 2019; 90 (4): 298–305
patients to confirm the diagnosis and initiate treatment, we 
may lacked only few patients from general practitioners. 
Information on death, available from the Danish Civil Reg-
istration System (Schmidt et al. 2014) and Statistics Norway, 
was linked to each patient in the national registers before 
transferring the data to NARA. 
Covariates 
Information on comorbidity was collected from the DNRP 
and NPR before transferring to the NARA database. For all 
included THA patients, we identified all primary and second-
ary discharge diagnoses for all hospitalizations and hospital 
specialist outpatient visits that occurred 1 year prior to the 
time of surgery. We computed the Charlson Comorbidity Index 
(CCI) score for each patient at the time of surgery. We defined 
3 comorbidity levels: a score of 0 (low), given to patients with 
no previous record of diseases included in the CCI; a score of 
1–2 (medium); and a score of 3 or more (high). Further vari-
ables were included as confounders: age and sex at the time 
of THA, year of primary THA, fixation type (cemented, unce-
mented, and hybrid/inverse hybrid fixation), and start of throm-
boprophylaxis (pre- or postoperative). In addition, we obtained 
information on the use of acetylsalicylic acid (both low-dose 
and high-dose), vitamin K antagonists, and platelet inhibi-
tors (clopidogrel, prasugrel, and ticagrelor) from the Danish 
National Database of Reimbursed Prescriptions (Johannesdot-
tir et al. 2012) and Norwegian Prescription Database (Furu 
2008) during the 2 years preceding the primary THR. 
Statistics
We used the cumulative incidence function to compute the 
90-day risk of VTE, major bleeding, and death, considering 
death as competing risk. We used Cox regression to compute 
crude and hazard ratios (HRs) adjusted for potential con-
founding factors with 95% confidence intervals (CIs). By 
application of log–log plots and Cox proportional hazards, the 
statistical model was found suitable. Follow-up started on the 
day of primary THA and ended either on the day of discharge 
from the primary hospitalization (if outcome occurred in the 
hospital), on the day of readmission for VTE/bleeding, date of 
death, emigration, or 90 days after surgery, whichever came 
first. All analyses were repeated stratifying on age, sex, CCI, 
thromboprophylaxis start, and country of origin in order to 
study the potential difference in effect of duration of thrombo-
prophylaxis on outcomes in subgroups of patients. 
Patients were included in each exposure category according 
to initial treatment assignment. Therefore, in the main analy-
ses we started follow up at the time of THA surgery to exam-
ine the effect of initial assigned treatment on VTE/bleeding/
death risk (according to intent to treat approach).
Sensitivity analyses
We tested the robustness of the results in a series of sensitiv-
ity analyses. 1st, the risk of all-cause mortality was calcu-
lated. 2nd, the risk of VTE and all-cause mortality defined 
as any DVT, non-fatal PE or all-cause mortality was calcu-
lated. 3rd, we analyzed data only for patients that were alive 
at day 7 or day 14 post-surgery without any VTE event during 
the first 7 or 14 postoperative days. These data will mimic 
randomization start in some clinical trials, which compares 
extended prophylaxis with placebo given after the 7th day 
(Eikelboom et al, 2001). In addition, these analyses should 
contribute to understanding of immortal time bias. 4th, we 
changed exposure definition to short-term (1–7 days), stan-
dard (8–14 days), or extended (≥ 15 days), since some hos-
pitals provide prophylaxis using weeks as guideline. 5th, we 
ignored revision as a competing risk. 6th, we performed clus-
ter analyses at hospital level in order to consider unmeasured 
hospital specific confounders. 7th, we analyzed data only for 
patients without use of acetylsalicylic acid before surgery. 
Analyses were performed using SAS V. 9.4 (SAS Institute 
Inc., Cary, NC, USA). 
All diagnosis codes used to identify VTE and major bleed-
ing after THA are presented in Appendix 1 (see Supplemen-
tary data).
Ethics, funding, and potential conflicts of interest
The study was approved by the Danish Data Protection 
Agency (Region of Central Denmark Jr. nr. 1-16-02-743-14) 
and Regional Ethical Committee of western Norway (Ref. 
2015/880/REK Vest). No funding was received for this study 
and the authors report no conflicts of interest.
Results
Among the 55,540 THA patients operated in Denmark during 
2010–2014 and Norway during 2008–2013, 15% received 
short, 31% received standard, and 45% received extended 
thromboprophylaxis treatment. Data regarding duration of 
treatment were missing in 9% (Table 1).
Compared with patients who received standard duration 
of treatment, patients with short duration of treatment were 
slightly younger, included fewer females, included fewer 
patients with CCI score medium and high, included fewer 
patients who received acetylsalicylic acid but more patients 
who received vitamin K antagonists and platelet inhibitors, 
and were more likely to undergo uncemented or hybrid THA 
in Denmark. On the other hand, patients with extended dura-
tion of treatment were also slightly younger, included more 
females, included more patients with CCI score medium and 
high, included fewer patients who received vitamin K antago-
nists and platelet inhibitors, and were less likely to undergo 
uncemented or hybrid THA. 
In the group with short duration of treatment, 8% were pre-
scribed prophylaxis for 1 day, 20% were prescribed treatment 
for 2 days, 34% of patients were prescribed prophylaxis for 
3 days, 17% were prescribed treatment for 4 days, and 17% 
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were prescribed treatment for 5 days. In the group with stan-
dard duration of thromboprophylaxis, 47% of patients were 
prescribed treatment for 7 days whereas 22% and 24% were 
prescribed treatment for 10 and 14 days, respectively. In the 
group with extended treatment duration, 12%, 20%, and 46% 
of patients received thromboprophylaxis for 28 days, 30 days, 
and 35 days, respectively. In the group with short-term treat-
ment duration, 44% received low-molecular-weight heparin, 
compared with 86% and 71% in the group with standard treat-
ment and extended duration of treatment. 
Within 90 days of surgery, cumulative incidences of VTE 
were 1.1% for patients prescribed short-term thrombopro-
phylaxis, and 1.0% for both standard and extended treatment 
(Figure). This correspond to the adjusted HRs for VTE of 1.1 
(CI 0.8–1.5) and 0.9% (CI 0.8–1.2) for patients prescribed 
short-term and extended thromboprophylaxis compared with 
standard thromboprophylaxis treatment (Table 2). 
Cumulative incidences of VTE/death as one outcome within 
90 days were 1.5% for patients prescribed short-term throm-
boprophylaxis, 1.4% for standard treatment duration, and 
1.3% for extended treatment duration. The adjusted HRs for 
pared with standard treatment. However, absolute risk differ-
ences were 0.4% and 0.5%, respectively. No increased risk 
for VTE and VTE/death was observed for male patients with 
short treatment duration, or for female/male patients receiving 
extended treatment compared with standard treatment. Strati-
fication on different age and CCI score groups produced the 
estimates similar to overall risk estimates for any outcome. 
Stratification on start of thromboprophylaxis showed that 
short treatment started postoperatively was associated with 
increased risk of dying (adjusted HR was 1.8, CI 1.1–3.1 and 
the absolute risk difference was 0.2%), whereas short treat-
ment started preoperatively was associated with reduced risk 
of dying (adjusted HR was 0.5, CI 0.2–1.2 and the absolute 
risk difference was 0.3%) compared with patients with stan-
dard treatment with post- and preoperative start, respectively. 
No difference in risk of dying was observed for patients start-
ing extended treatment either post- or preoperatively. The 
adjusted HR for dying for short treatment started postopera-
tively vs. standard treatment started postoperatively was 2.2 
(CI 1.1–4.2) among patients without use of acetylsalicylic 
acid before surgery. 
Table 1. Patient characteristics, medication use, and surgery-related factors of 55,540 
patients undergoing THA in Denmark in 2010–2014 and Norway in 2008–2013
 Duration of thromboprophylaxis 
 Missing Short Standard Extended Total 
Factor n (%) n (%) n (%)n (%) n (%) n (%)
Total 5,058 (100) 8,333 (100) 17,009 (100) 25,140 (100) 55,540 (100)
Age group 
 10–59 757 (15) 1,487 (18) 2,790 (16) 3,811 (15.2) 8,845 (16)  
 60–69 1,670 (33) 2,819 (34) 5,646 (33.2) 8,665 (35) 18,800 (34)
 70–79 1,877 (37) 2,890 (35) 6,129 (36) 8,971 (38) 19,867 (36)
 80+ 754 (15) 1,137 (14) 2,444 (14) 3,693 (15) 8,028 (15)
Sex 
 Female 2,967 (59) 4,586 (55) 10,326 (61) 15,975 (64) 33,854 (61)
 Male 2,091 (41) 3,747 (45) 6,683 (39) 9,165 (36) 21,686 (39)
Charlson Comorbidity Index 
 Missing data 27 (0.5) 2 (0) 26 (0.2) 215 (1) 270 (1)
 Low 4,158 (82) 7,352 (88) 14,175 (83) 20,371 (81) 46,056 (83)
 Medium 770 (15) 864 (10) 2,486 (15) 3,975 (16) 8,095 (15)
 High 103 (2) 115 (1) 322 (2) 579 (2) 1119 (2)
Acetylsalicylic acid 
 No  3,815 (75) 6,594 (79) 13,108 (77) 19,202 (76) 42,719 (77)
 Yes 1,243 (25) 1,739 (21) 3,901 (23) 5,938 (24) 12,821 (23)
Clopidogrel/prasugrel/ticagrelor 
 No 4,949 (98) 8,107 (97) 16,635 (98) 24,727 (98) 54,418 (98)
 Yes 109 (2) 226 (3) 374 (2) 413 (2) 1,122 (2)
Marevan/marcoumar/dabigratran/apixaban/rivaroxaban
 No 4,550 (90) 7,699 (92) 15,764 (93) 23,970 (95) 51,983 (94)  
 Yes 508 (10) 634 (8) 1,245 (7) 1170 (5) 3557 (6)
Type of fixation 
 Missing data 72 (1) 16 (0) 178 (1) 343 (1) 609 (1)  
 Cementeret 1,530 (30) 481 (6) 5,164 (30) 8,971 (36) 16,146 (29)
 Uncementeret 1,989 (39) 5,934 (71) 8,625 (51) 9,123 (36) 25,671 (46)
 Hybrid 491 (10) 1,691 (20) 855 (5) 774 (3) 3,811 (7)
 Reverse hybrid 976 (19) 211 (3) 2,187 (13) 5,929 (24) 9,303 (17)
Start of thromboprophylaxis 
 Missing data 1,056 (21) 51 (1) 555 (3) 1,866 (7) 3,528 (6)   
 Preoperative 1,293 (26) 2,677 (32) 4,892 (29) 6,334 (25) 15,196 (27)
 Postoperative 2,709 (54) 5,605 (67) 11,562 (68) 16,940 (67) 36,816 (66)
VTE/death were 1.1 (CI 0.9–1.4) for 
patients prescribed short-term and 0.9 
(CI 0.8–1.1) for extended treatment, 
compared with standard thromboprophy-
laxis treatment. 
Within 90 days of surgery, cumula-
tive incidences of major bleeding were 
0.7% for patients treated with both short 
and standard treatment, and 0.5% for 
extended thromboprophylaxis treatment 
(Figure). The adjusted HRs for major 
bleeding were 1.1 (CI 0.8–1.6) for short-
term treatment and 0.8 (CI 0.6–1.1) for 
extended duration of treatment compared 
with standard treatment. 
The risk of death within 90 days of sur-
gery was 0.5% among patients prescribed 
short-term treatment, 0.4% for standard 
treatment, and 0.3% for extended treat-
ment. The adjusted HRs for death were 
1.2 (CI 0.8–1.8) for short-term duration 
of treatment, and 0.8 (CI 0.5-1.1) for 
extended duration of treatment, compared 
with standard duration of treatment. 
Analyses stratified on country of 
origin showed similar results to those of 
the overall population for all outcomes 
(Appendix 2, available from the authors). 
Stratification on sex showed that females 
receiving short treatment duration were 
associated with increased risk of VTE 
and VTE/death (adjusted HR were 1.6, 
CI 1.1–2.2 and 1.6, CI 1.2–2.2) com-
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We found similar risk estimates derived from the cluster 
analyses and those derived from analyses without cluster-
ing for hospitals (data not shown). In addition, analyses with 
slight change of exposure categories definition, analyses not 
including revision as competing risk into appropriate models, 
or analyses among THA patients who were alive at day 7/14 
without any VTE event during the period from the day of 
primary THA to 7/14 days after, did not affect overall study 
results (data not shown). 
Discussion 
In this large population-based study including 55,540 THA 
patients from routine clinical practice, we found no overall 
difference in risk of VTE, VTE/death, or major bleeding with 
respect to the duration of pharmacological thromboprophy-
laxis. However, differences between duration of treatments 
were observed when stratifying on sex and start of thrombo-
prophylaxis treatment, suggesting that female patients with 
short treatment have increased risk of VTE and patients with 
short treatment initiated postoperatively have increased risk 
of dying. This could be used to guide preventive treatment for 
subgroups of patients; however, low absolute risk difference 
estimates should be taken into consideration. 
Strengths and weaknesses 
Completeness and validity of data in the Danish Hip Arthro-
plasty Registry and Norwegian Arthroplasty Register are doc-
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Table 2. Effect of thromboprophylaxis treatment duration on the risk of death, thromboembolism 
(VTE), major bleeding, VTE, and death, and risk of revision in total hip arthroplasty patients within 90 
days of surgery, with standard treatment as the reference
  Duration of     90 days
  thrombo- Outcome Number Crude Adjusted cumulative
Outcome prophylaxis (n) at risk HR (95% CI)  HR (95% CI)  incidence (95% CI)
Death Short 39 8,333 1.3 (0.9–1.9) 1.2 (0.8–1.8) 0.5% (0.3–0.6)
Death Standard 62 17,009 1.0 1.0 0.4% (0.3–0.5)
Death Extended 72 25,140 0.8 (0.6–1.1) 0.8 (0.5–1.1) 0.3% (0.2–0.4)
VTE Short 89 8,333 1.0 (0.8–1.3) 1.1 (0.8–1.5) 1.1% (0.9–1.3)
VTE Standard 176 17,009 1.0 1.0 1.0% (0.9–1.2)
VTE Extended 245 25,140 0.9 (0.8–1.1) 0.9 (0.8–1.2) 1.0% (0.9–1.1)
Bleeding Short 56 8,333 1.0 (0.7–1.4) 1.1 (0.8–1.6) 0.7% (0.5–0.9)
Bleeding Standard 116 17,009 1.0 1.0 0.7% (0.6–0.8)
Bleeding Extended 128 25,140 0.7 (0.6–1.0) 0.8 (0.6–1.1) 0.5% (0.4–0.6)
VTE/death Short 125 8,333 1.1 (0.9–1.4) 1.1 (0.9–1.4) 1.5% (1.3–1.8)
VTE/death Standard 233 17,009 1.0 1.0 1.4% (1.2–1.6)
VTE/death Extended 315 25,140 0.9 (0.8–1.1) 0.9 (0.8–1.1) 1.3% (1.1–1.4)
HR = hazard ratio; CI = confidence interval.
HR adjusted for age, sex, Charlson Comorbidity Index score, type of fixation, start of thromboprophy-
laxis, as well as acetylsalicylic acid, clopidogrel/prasugrel/ticagrelor, marevan/marcumar/dabigatran/
apixaban/rivaroxaban used before surgery.
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son et al. 2005). The positive predictive value of VTE and 
major bleeding is 75–95% with an accuracy of 94–100% of 
the comorbid diagnoses included in the CCI (Bakken et al. 
2004, Thygesen et al. 2011, Sundboll et al. 2016). Due to pro-
spective registration of data, misclassification of VTE/bleed-
ing is not likely to be related to registration of exposure status 
(thus, duration of treatment). Therefore, our HRs should be 
unbiased. However, our absolute cumulative incidences of 
VTE/bleeding are underestimated. Information on death and 
migration was available from the Civil Registration System, 
allowing for nationwide cohort studies with virtually complete 
follow-up (Schmidt et al. 2014). Further, selection bias in our 
study is low since we included all THA patients treated in 
many departments irrespective of specific patient characteris-
tics or willingness to participate in the study. 
We lack data on duration of treatment for 9% of patients. 
However, the median age, sex, and comorbidity level for the 
excluded patients were similar to those of patients included in 
the study population. In light of prospective collection of data 
on duration of treatment and subsequent outcomes of interest, it 
is unlikely that missing data on duration of treatment occurred 
systematically. Hypothetically, if patients’ compliance with the 
treatment after discharge had changed, which is most worrisome 
for patients included in the extended treatment group, this could 
have affected our results in any direction. Although we were able 
to adjust for a number of potential confounders, including pre-
admission anticoagulant medication, unmeasured and residual 
confounding, as well as confounding by indication, cannot be 
accounted for entirely in an observational study, in particular 
when studying the effect of treatment. We have, however, 
performed a number of sensitivity analyses in order to elucidate 
any confounding bias.
We have used the cumulative incidence method to estimate 
crude failure (crude VTE or crude bleeding risk), which is the 
likely number of VTE or bleeding incidents we see in clinical 
practice and consists of both the failure of the VTE/bleeding 
and the mortality process (Sayers et al. 2018). In Table 2 we 
present both number of failures (VTE/bleeding) and number 
of patients at risk, which allows for estimation of net failure 
(the Kaplan–Meier estimates with immortal patients). It is 
worth noting that the difference between cumulative incidence 
and Kaplan–Meier estimates is very small, most likely due to 
short-term follow-up and low mortality in the exposure groups. 
Comparison with other studies
2 recently published systematic reviews based on clinical trials 
(Forster and Stewart 2016, Trevisol et al. 2018) both concluded 
that extended duration thromboprophylaxis should be considered 
to prevent VTE, when undergoing THA. Forster et al. furthermore 
specified that the evidence for extended duration was moderate, 
and that the benefit should be weighed against the increased 
risk of minor bleeding. Likewise, 2 systematic reviews based on 
older clinical trials (Hull et al. 2001, Sobieraj et al. 2012) also 
concluded that extended thromboprophylaxis is more efficacious 
than shorter thromboprophylaxis for preventing VTE or VTE-
related deaths while increasing the risk of minor bleeding. These 
results do not correlate with our findings. 
However, in a systemic review, O’Donnell et al. (2003) 
concluded that the absolute reduction in symptomatic VTE 
attributed to extended prophylaxis in some clinical trials 
seems to have been overestimated. The authors suggested that 
the assessment of symptomatic VTE in clinical trials did not 
occur independently of the routine venography results, which 
could have led to an overestimation of the symptomatic VTE 
risk and the absolute risk reduction attributed to extended 
prophylaxis. A prospective, observational, non-interventional, 
phase IV study of 3,914 consecutive patients who underwent 
total hip or knee arthroplasty during 2010 to 2012 reported 
that treatment with rivaroxaban for 15 days was protective 
against symptomatic VTE without excess risk of major 
bleeding (Gomez et al. 2017). The absolute risk of VTE and 
bleeding in that study was 0.5% and 0.3%, respectively. In 
the same study, the authors calculated that treating all 1,444 
primary THA patients for 35 days with rivaroxaban could 
theoretically prevented 1–3 symptomatic proximal DVTs. 
Based on 16,865 THA patients operated from 2010 through 
2012 in Denmark, we have previously reported that there is 
no difference in the risk of VTE and bleeding with respect 
to duration of thromboprophylaxis (Pedersen et al. 2015). 
A study including only patients from fast-track departments 
where thromboprophylaxis is provided for 1–2 days reported 
an absolute risk of VTE within 90 days of 0.5% (Petersen et 
al. 2018). These absolute VTE risk estimates are similar to 
estimates observed in the current study and estimates from 
clinical trials. 
Extended prophylaxis is further challenged by aspirin 
as potential prophylaxis treatment. Azboy et al. (2017) 
performed a review on aspirin studies, concluding that there 
is convincing evidence that aspirin is an effective, inexpensive 
and safe VTE prevention treatment in THA patients without 
increased risk of bleeding. Safety of aspirin was reported 
when administered as part of a hybrid strategy that follows a 
short course of anticoagulation in select low-risk populations, 
but also when administered alone in appropriately screened 
patients (Anderson et al. 2018). Since the rates of VTE and 
bleeding are very low, the potential benefits of extended 
prophylaxis may not be worth discussing. The orthopedic 
surgeons are currently discussing not how long, but how short 
a duration of thromboprophylaxis should be given, targeting 
extended thromboprophylaxis to high-risk patients. 
Our stratified analyses suggest that the start of thrombo-
prophylaxis might play a role since patients who started short 
treatment postoperatively had an increased risk of dying. This 
is in line with the latest findings from Norway, showing that 
THA patients who started thromboprophylaxis preoperatively vs. 
those who started postoperatively have adjusted odds ratio for 
dying of 0.7 (CI 0.5–1.1), whereas the risk of other postoperative 
complications was similar in the two groups (Borgen et al. 2017). 
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Conclusions
In this large cohort study including 55,540 THA patients 
from a routine clinical practice in Denmark and Norway, we 
found no overall clinically relevant difference in risk of VTE 
and bleeding with respect to the duration of pharmacological 
thromboprophylaxis. However, higher relative risk of dying 
for short treatment initiated postoperatively was observed. 
The significance of these data should be explored further, and 
short-term thromboprophylaxis started preoperatively should 
be considered. 
Supplementary data
Appendix 2. Stratified analyses: cohort of first primary THA 
operation in Denmark in 2010–2014 and Norway in 2008–
2013 stratified on age groups, CCI, country, sex, and start pre-
operatively versus postoperatively is available on request from 
the authors. 
Appendix 1 is available as supplementary data in the online 
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